Clinical characteristics of intermediate uveitis in adult Turkish patients

·AIM: To describe the clinical characteristics of Turkish patients with intermediate uveitis(IU) and to investigate the effect of clinical findings and complications on final visual acuity(VA).·METHODS: We retrospectively analyzed the medical records of patients with IU who had at least 6mo of follow-up and were older than 16 y.· RESULTS: A total of 78 eyes of 45 patients were included in the study and the mean follow-up period was19.4mo. The mean age at the time of presentation was42.9s. Systemic disease associations were found in17.7% of cases; sarcoidosis(8.8%) and multiple sclerosis(6.6%) were the most common diseases. Recurrence rate(odds ratio=45.53; 95%CI: 2.181-950.58), vitritis equals to or more than 3+ cells(odds ratio =57.456; 95%CI: 4.154-794.79) and presenting with VA less than 20/40(odds ratio =43.81; 95% CI: 2.184-878.71) were also found as high risk factors for poor final VA. At the last follow-up examination, 67.9% of eyes had VA of 20/40 or better.·CONCLUSION: IU is frequently seen at the beginning of the fourth decade of life. The disease is most commonly idiopathic in adult Turkish patients. Patients with severe vitritis at presentation and patients with frequent recurrences are at high risk for poor visual outcome.

Uveitis secondary to cancer therapeutics

Cancer cells provide a therapeutic challenge as they impede the immune system and its response to malignancy.Checkpoint inhibitors and targeted therapy provide novel methods for the treatment of these metastases.These use of immunotherapy and targeted therapy is widespread,with indications including metastatic melanoma,squamous cell carcinoma,non-small cell lung cancer,colon cancer,gastric cancer,renal cell carcinoma,Merkel cell carcinoma and urothelial cancer.Checkpoint inhibitors act upon three main receptors or ligands to achieve this goal:cytotoxic T-lymphocyte antigen-4(CTLA-4),programmed death protein(PD-1)and programmed death ligand-1(PD-L1).Additionally,targeted therapies counter the mutations leading to cancer cell proliferation,which include the mitogen-activated protein kinase(MEK)pathway and BRAF enzyme.However,they are known to cause ocular side effects in up to 1%of patients,with uveitis comprising a fraction of these patients.These secondary uveitis manifestations can present with severity ranging from solitary anterior uveitis to panuveitis,sometimes in concert with systemic manifestations such as Vogt-Koyanagi-Harada(VKH)-like syndrome.The uveitis caused by these medications can present both diagnostic and treatment challenges that can complicate patient care.Systemic steroids have demonstrated mixed data regarding the reduction of cancer therapeutic efficacy,and as a result,immunotherapy and targeted therapy are often held when systemic steroids are used for immune-related adverse event(irAE)treatment.Local steroids,although prone to their own set of adverse effects,may therefore be preferable to systemic steroids in the treatment of uveitis secondary to cancer therapeutics.In this review,we provide an overview of uveitis secondary to targeted therapy and immunotherapy,as well as treatment considerations.

New options for uveitis treatment

Uveitis is one of the most important causes of blindness worldwide.Its etiology and pathogenesis are complicated and have not been well understood.The treatment for uveitis is predominantly based on steroids and immunosuppressants.However,systemic side effects limit their clinical application.With the advancement of molecular biology,some intravitreal implants and biologic agents have been used for the treatment of uveitis.Additionally,novel techniques such as gene therapy and RNA interference are being studied for using as uveitis therapy.This paper reviews recent advances in uveitis treatment.

Newer trends in tubercular uveitis:a case series with systemic correlation

AIM:To determine the spectrum of uveitis,causes of visual loss in systemic tuberculosis(TB),role of investigations and outcome after anti-TB therapy(ATT).METHODS:A retrospective study was conducted on 250 patients with systemic TB at a referral center in Chennai,South India from April 2016 to May 2019.Systemic workup comprised of Mantoux,chest X-ray,polymerase chain reaction(PCR)and QuantiFERON(QFT)TB Gold.Aqueous humor analysis by nested PCR or real time PCR(RT-PCR)and ancillary ophthalmic investigations such as fundus fluorescein angiography,optical coherence tomography were performed.RESULTS:Multifocal choroiditis and vasculitis were the most common manifestations(39%and 24%respectively)together accounting for 61%of cases and they had a higher risk of recurrence(3%).Pulmonary tuberculosis(PTB)was more frequently associated with uveitis(18%).Among those with extra-pulmonary tuberculosis(EPTB),uveitis occured in miliary TB(2%),bone(1%)and abdominal TB(1%).Complications such as cystoid macular edema,choroidal neovascular membranes and macular scarring caused visual loss.Aqueous humor analysis detected mycobacterium TB antigen.Collectively,systemic investigations such as chest X-ray,Mantoux test and those performed on blood samples such as PCR and QFT were positive in 39%of patients.In inconclusive patients,nested PCR and/or RT-PCR were done on aqueous humor samples and were diagnostic in 96%.A combination of tests was diagnostic in 92%.ATT in isolation in 71%and combined with corticosteroids in 29%was used for treatment of which signs of resolution and improvement in vision started as early as 6wk in those who were started immediately on corticosteroids and ATT and longer than 3mo in those on ATT alone.Prompt treatment with ATT and corticosteroids improved vision in 23%of our patients within 2mo.Vitritis with choroiditis causes cystoid macular oedema and requires longer duration of ATT.Vision improved in 69%.Complete resolution occurred in 75%and worsening in 12%.CONCLUSION:A combination of investigations guided by clinical suspicion helps in precise diagnosis.In diagnostic dilemmas analysis of ocular samples is reliable and confirmatory.Screening all patients and a multidisciplinary approach in TB(active,healed or during treatment)is recommended.

Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma

Hepatocellular carcinoma(HCC)is a high mortality neoplasm which usually appears on a cirrhotic liver.The therapeutic arsenal and subsequent prognostic outlook are intrinsically linked to the HCC stage at diagnosis.Notwithstanding the current deployment of treatments with curative intent(liver resection/local ablation and liver transplantation)in early and intermediate stages,a high rate of HCC recurrence persists,underscoring a pivotal clinical challenge.Emergent systemic therapies(ST),particularly immunotherapy,have demonstrate promising outcomes in terms of increase overall survival,but they are currently bound to the advanced stage of HCC.This review provides a comprehensive analysis of the literature,encompassing studies up to March 10,2024,evaluating the impact of novel ST in the early and intermediate HCC stages,specially focusing on the findings of neoadjuvant and adjuvant regimens,aimed at increasing significantly overall survival and recurrence-free survival after a treatment with curative intent.We also investigate the potential role of ST in enhancing the downstaging rate for the intermediate-stage HCC initially deemed ineligible for treatment with curative intent.Finally,we critically discuss about the current relevance of the results of these studies and the encouraging future implications of ST in the treatment schedules of early and intermediate HCC stages.

High-dose Chemotherapy Combined with Autologous Hematopoietic Stem Cell Transplantation as Frontline Therapy for Intermediate/High-risk Diffuse Large B Cell Lymphoma

The role of autologous hematopoietic stem cell transplantation(auto-HSCT)following high-dose chemotherapy has been validated and accepted as a standard treatment for patients with relapsed diffuse large B-cell lymphoma(DLBCL).However,its clinical efficacy as frontline therapy remains to be elucidated.This study aimed to examine the feasibility of frontline auto-HSCT for newly diagnosed intermediate/high-risk DLBCL patients.We retrospectively reviewed the data of 223 patients treated with frontline auto-HSCT or chemotherapy alone(year 2008-2014)from four hospitals.The median follow-up time was 29.4 months.Between the two treatment arms among the intermediate/high-risk DLBCL patients,the 3-year overall survival(OS)and progression-free survival(PFS)rates of patients given frontline auto-HSCT were 87.6%and 81.9%,respectively,and the chemotherapy-alone group showed 3-year OS and PFS rates of 64.9%and 59.59%,respectively.Compared with the chemotherapy-alone group,the frontline auto-HSCT could eliminate the adverse impact of non-germinal center B-cell(GCB)type.In addition,in the frontline auto-HSCT group,patients who achieved complete response(CR)at auto-HSCT had a longer survival time than those who did not achieve CR.Our results suggested that frontline auto-HSCT could improve the prognosis of intennediate/high-risk DLBCL patients.

An ROS-Responsive Antioxidative Macromolecular Prodrug of Caffeate for Uveitis Treatment

Uveitis is a sophisticated syndrome showing a high relevance with reactive oxygen species(ROS).Herein,an ROS-responsive PEGylated polypeptide based macromolecular prodrug of herbaceous antioxidant ethyl caffeate(EC)is designed via phenylboronic esters with improved solubility for the alleviation of uveitis.The antioxidative 4-hydroxybenzyl alcohol(HBA)and EC can be released from the macromolecular EC prodrug under the stimulation of ROS,which can effectively protect cells against oxidative stress-induced injury in an ROS-depletion way.The antioxidative and protective effects of the macromolecular EC prodrug in vivo are further verified in a uveitis mouse model.Overall,this work not only provides a handy method to synthesize a phenylboronic ester-bearing EC prodrug which is highly sensitive to pathological ROS,but also depicts a promising future to apply macromolecular antioxidative prodrugs in the treatment of uveitis as well as other ROS-related diseases.

Ocular syphilis:a case series of four patients and a review of the literature

Background:The incidence of syphilis has been increasing in the United States over the last two decades,with a more recent increase among women.Ocular syphilis is an uncommon but important complication of syphilis,most often presenting as posterior or panuveitis in late or latent syphilis of unknown duration.Untreated ocular syphilis may lead to permanent vision loss,underscoring the importance of appropriate evaluation and treatment of ocular syphilis.Case Description:In a retrospective,non-contiguous case series,we highlight four patients diagnosed and treated with ocular syphilis at a single institution.Four presentations of ocular syphilis are illustrated:anterior and intermediate uveitis,optic neuritis,posterior uveitis,and panuveitis.All patients initially presented with a decreased visual acuity(VA).One patient had a previous diagnosis of human immunodeficiency virus(HIV).Three patients were treated with intravenous(IV)penicillin and one patient with IV ceftriaxone.All had a return to their baseline VA after their course of treatment.Conclusions:Syphilis may go undetected without a high index of clinical suspicion due to its nonspecific presentations.All patients with ocular inflammation should have syphilis testing as a part of their infectious workup with both treponemal and non-treponemal testing.Patients diagnosed with syphilis and are not known to be HIV-negative should undergo testing for HIV due to the high rate of co-infection.Early diagnosis and prompt treatment after onset of symptoms may contribute to a more favorable prognosis for ocular syphilis.

肿瘤治疗电场在肿瘤治疗中的应用和机制研究进展

[背景]肿瘤治疗领域缺乏高效、安全的非侵入式治疗方法.近年来,肿瘤治疗电场(tumor treating fields,TTFields)作为一种新兴的非侵入性物理治疗技术,通过释放中频、低强度的交变电场有效抑制肿瘤生长,引发的副作用较小.[进展]目前TTFields已被广泛应用于各类肿瘤治疗的临床研究中,包括脑胶质瘤、间皮质瘤、非小细胞肺癌、胰腺癌、卵巢癌、肝癌及胃癌等.TTFields通过向生物分子施加生物物理力,扰乱肿瘤细胞的生物学功能从而抑制其生长,但具体分子机制尚不明确.为研究TTFields在肿瘤治疗中的分子机制,研究人员通过设计和搭建不同电极和交变电场发生平台,在体外研究TTFields对肿瘤细胞的作用机制.研究发现TTFields干扰细胞分裂、DNA修复、自噬、细胞迁移和细胞膜通透性等生物学过程,也影响血脑屏障、血管生成和肿瘤免疫等肿瘤微环境.[展望]本文回顾了近年来TTFields在肿瘤治疗中的应用、用于体外研究的电极设计和电场发生平台,及其潜在的抗肿瘤机制.然而,TTFields抑制肿瘤生长的分子机制仍需深入研究,评估其对能够自我更新的非肿瘤细胞和终端分化细胞的影响,以减少可能的副作用.这些研究将有助于提升TTFields的治疗潜力,为更多恶性肿瘤的治疗开辟新的可能性.

中频乳腺治疗仪联合中医药对乳腺腺病干预的效果及对癌变的影响

目的观察中频乳腺治疗仪联合中医药干预对乳腺腺病的治疗效果及对癌变的影响。方法将122例乳腺腺病患者按照随机数字表法分为2组,对照组61例予中医药干预,观察组61例在对照组基础上联合中频乳腺治疗仪治疗。2组均干预3个月。比较2组干预前后肿块硬度评分、健康知识评分及干预后依从性评分、满意度评分,统计肿块缩小一半时间和完全消失时间,比较干预后6个月、1年肿块复发率和乳腺影像报告和数据系统(BI-RADS)分级升高率。结果2组干预后肿块硬度评分均较本组干预前降低(P<0.05),且观察组干预后低于对照组(P<0.05)。观察组肿块缩小一半时间和完全消失时间均短于对照组(P<0.05)。2组干预后健康知识评分均较本组干预前升高(P<0.05),且观察组干预后均高于对照组(P<0.05)。观察组干预后6个月、1年肿块复发率和BI-RADS分级升高率均低于对照组同期(P<0.05)。观察组干预后依从性评分均高于对照组(P<0.05)。观察组干预后满意度评分均高于对照组(P<0.05)。结论中频乳腺治疗仪联合中医药干预治疗乳腺腺病效果可靠,可促进肿块缩小,提高患者的健康知识水平,降低复发率和癌变风险,提高患者的依从性和满意度。

中间剂量计算模式对食管癌容积旋转调强放射治疗计划的影响

目的探讨中间剂量计算(IDC)模式对食管癌容积旋转调强放射治疗(VMAT)计划的影响。方法选取2021年12月至2022年8月医院收治的18例食管癌患者,在Eclipse15.6治疗计划系统上重新设计VMAT计划,分为未应用IDC模式计划和应用IDC模式计划,比较两种计划的靶区和危及器官(OARs)的剂量学差异。结果两种计划靶区的D_(98)、D_(2)、D_(mean)、适形度指数(CI)和均匀性指数(HI)等参数比较,差异有统计学意义(P<0.05)。两种计划双肺的V_(5)、V_(10)、V_(20)、V_(30)和D_(mean)及脊髓D_(max)比较,差异无统计学意义(P>0.05),但应用IDC模式计划的心脏V_(30)、V_(40)、D_(mean)均低于未应用IDC模式计划,差异有统计学意义(P<0.05)。结论应用IDC模式计划较未应用IDC模式计划具有更好的靶区适形度和均匀性,同时降低了OARs剂量,因此,应用IDC模式计划可以提高食管癌VMAT计划的质量。

Magnetic resonance-guided focused ultrasound for essential tremor:a prospective,single center,single-arm study

The safety and effectiveness of magnetic resonance-guided focused ultrasound thalamotomy has been broadly established and validated for the treatment of essential tremor.In 2018,the first magnetic resonance-guided focused ultrasound system in Chinese mainland was installed at the First Medical Center of the PLA General Hospital.This prospective,single center,open-label,single-arm study was part of a worldwide prospective multicenter clinical trial(ClinicalTrials.gov Identifier:NCT03253991)conducted to confirm the safety and efficacy of magnetic resonance-guided focused ultrasound for treating essential tremor in the local population.From 2019 to 2020,10 patients with medication refractory essential tremor were recruited into this open-label,single arm study.The treatment efficacy was determined using the Clinical Rating Scale for Tremor.Safety was evaluated according to the incidence and severity of adverse events.All of the subjects underwent a unilateral thalamotomy targeting the ventral intermediate nucleus.At the baseline assessment,the estimated marginal mean of the Clinical Rating Scale for Tremor total score was 58.3±3.6,and this improved after treatment to 23.1±6.4 at a 12-month follow-up assessment.A total of 50 adverse events were recorded,and 2 were defined as serious.The most common intraoperative adverse events were nausea and headache.The most frequent postoperative adverse events were paresthesia and equilibrium disorder.Most of the adverse events were mild and usually disappeared within a few days.Our findings suggest that magnetic resonance-guided focused ultrasound for the treatment of essential tremor is effective,with a good safety profile,for patients in Chinese mainland.

标准化早期康复护理与中频治疗对卒中后吞咽障碍的效果探讨

目的:分析标准化早期康复护理联合中频治疗在脑卒中后吞咽障碍中的应用效果。方法:选取2021年1月至2023年10月蚌埠医科大学第一附属医院收治的64例脑卒中后吞咽障患者,分为对照组与实验组,各32例,对照组采用常规护理干预,实验组实施标准化早期康复护理联合中频治疗干预,比较两组心理状态(HADS、SPBS)、吞咽功能(SSA)、不良事件、生活质量(SWAL-QOL)、康复效果。结果:干预后实验组HADS评分、SPBS评分、SSA评分、不良事件发生率均低于对照组(P<0.05),SSA、SWAL-QOL评分、康复优良率均高于对照组(P<0.05)。结论:标准化早期康复护理与中频治疗联合应用,利于患者心理状态、吞咽功能、生活质量改善,能够减少患者不良事件发生率。

中频治疗仪联合牵引疗法对腰椎间盘突出伴坐骨神经痛患者疼痛和关节功能恢复的影响

目的探讨中频治疗仪和牵引疗法联合应用对腰椎间盘突出伴坐骨神经痛的治疗效果。方法选取2022年2月—2024年1月广饶县人民医院收治的96例腰椎间盘突出伴坐骨神经痛患者为研究对象,按照随机信封法将其分为对照组(n=39)与观察组(n=57)。对照组采用常规物理牵引治疗,观察组在对照组的基础上采用中频治疗仪治疗。比较两组患者的临床疗效、腰椎功能、临床症状改善情况和炎症因子水平。结果观察组治疗总有效率为96.49%,高于对照组的82.05%,差异有统计学意义(P<0.05)。治疗前,两组日本骨科协会评估量表(JOA)、Oswestry功能障碍指数(ODI)、疼痛视觉模拟(VAS)评分和腰屈曲范围比较,组间差异无统计学意义(P>0.05);治疗后,两组JOA评分均高于治疗前,腰屈曲范围均大于治疗前,VAS和ODI评分均低于治疗前,且观察组JOA评分高于对照组,腰屈曲范围大于对照组,VAS和ODI评分均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组前列腺素E_(2)(PGE_(2))、肿瘤坏死因子-ɑ(TNF-ɑ)和白细胞介素-6(IL-6)水平比较,组间差异无统计学意义(P>0.05);治疗后,两组TNF-ɑ、PGE_(2)、IL-6水平均低于治疗前,且观察组均低于对照组,差异有统计学意义(P<0.05)。结论在腰椎间盘突出伴坐骨神经痛的临床治疗中,中频治疗仪和物理牵引联合治疗能够有效促进患者疼痛缓解,提升腰椎功能和活动度,减轻无菌性炎症刺激,改善临床症状,治疗实用性较高。

中频脉冲治疗联合深层肌康复锻炼对腰椎间盘突出症术后患者腰椎功能的影响

目的探究中频脉冲治疗联合深层肌康复锻炼对腰椎间盘突出症(LDH)术后患者腰椎功能的影响。方法选择2020年6月—2023年6月梁山县人民医院收治的70例LDH患者为研究对象,按随机数字表法将其分为对照组及观察组,每组35例。两组均采用一般支持治疗,在此基础上,对照组进行深层肌康复锻炼,观察组采用中频脉冲治疗仪联合深层肌康复锻炼。对比两组患者的腰椎功能、疼痛程度、生活质量、腰腹肌肌力及脊髓神经功能。结果干预4周后,观察组的Oswestry功能障碍指数、疼痛视觉模拟评分均低于对照组,组间差异有统计学意义(P<0.05)。干预4周后,观察组的健康调查简表评分为(72.36±8.57)分,高于对照组的(62.22±11.74)分,差异有统计学意义(P<0.05)。干预4周后,观察组的腰背肌、腹肌肌力均大于对照组,组间差异有统计学意义(P<0.05)。干预4周后,观察组的日本骨科协会评分高于对照组,差异有统计学意义(P<0.05)。结论中频脉冲治疗联合深层肌康复锻炼治疗LDH术后患者,有助于减轻其疼痛程度,改善腰椎功能、腰腹肌肌力和脊髓神经功能,提高其生活质量。

Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation:Where do we stand?

Liver transplantation (LT) for hepatocellular carcinoma (HCC) within Milan criteria is a widely accepted optimal therapy. Neo-adjuvant therapy before transplantation has been used as a bridging therapy to prevent dropout during the waiting period and as a down-staging method for the patient with intermediate HCC to qualify for liver transplantation. Transarterial chemoembolization and radiofrequency ablation are the most commonly used method for locoregional therapy. The data associated with newer modalities including drug-eluting beads, radioembolization with Y90, stereotactic radiation therapy and sorafenib will be discussed as a tool for converting advanced HCC to LT candidates. The concept &#x0201c;ablate and wait&#x0201d; has gained the popularity where mandated observation period after neo-adjuvant therapy allows for tumor biology to become apparent, thus has been recommended after down-staging. The role of neo-adjuvant therapy with conjunction of &#x0201c;ablate and wait&#x0201d; in living donor liver transplantation for intermediate stage HCC is also discussed in the paper.

Non-drug therapies for acute gouty arthritis treatment

The incidence and prevalence of acute gouty arthritis are increasing with the total prevalence ofgout in China. Non-drug therapies are now being increasingly evaluated for its role in acute andchronic gout with less toxic and side effects and better therapeutic effects. This reviewsummarized that activated coarse fiber, inhibited fine fiber, the influence on5-hydroxytryptamine (5-HT), increased K+ and the anti-inflammation factors were the possiblemechanisms of non-drug therapies for the acute gouty arthritis;This review also introduced thetraditional non-drug therapies and modern non-drug therapies;The traditional non-drugtherapies, including acupuncture, puncture cupping can significantly alleviate acuteinflammation of gout joints and prevent joint dysfunction without obvious toxic and side effects;Modern non-drug therapies, such as laser therapy, electrotherapy, magnetic therapy andultrasonic therapy, also could effectively improve swelling and pain symptoms and joint functionof patients with acute gouty arthritis, and reduce the levels of C-reactive protein, serum uricacid and erythrocyte sedimentation rate. To sum up, the non-drug therapies, especially theincreasing varieties of modern physical therapies, have achieved good effects in the treatmentof acute gouty arthritis with the characteristics of less toxicity and side effects, which are worthyof wide use.

手法按摩配合中频理疗治疗小儿面瘫的临床效果

目的:分析手法按摩配合中频理疗治疗小儿面瘫的临床效果。方法:选取2018年1月—2021年6月于信宜市人民医院诊治的64例面瘫患儿为研究对象。根据随机数表法将其分为对照组和研究组,各32例。对照组给予中频理疗,研究组给予手法按摩配合中频理疗。比较两组临床疗效,治疗前后面神经功能及面部情况。结果:治疗后,研究组总有效率为96.88%,高于对照组的81.25%,差异有统计学意义(P<0.05)。治疗后,研究组面神经功能评分为(9.15±1.89)分,低于对照组的(12.49±2.76)分,差异有统计学意义(P<0.05)。治疗后,研究组社会生活功能(FDIS)评分为(21.46±3.18)分,高于对照组的(18.24±2.27)分,躯体功能(FDIP)评分为(9.52±0.89)分,低于对照组的(11.29±1.03)分,差异有统计学意义(P<0.05)。结论:手法按摩配合中频理疗治疗小儿面瘫的临床效果较好,能有效改善患儿面神经指标,且预后效果较好。

中西医结合治疗葡萄膜炎研究进展

葡萄膜炎是一种常见的致盲性眼病,多发于青壮年,易合并全身性自身免疫性疾病。近几年来,现代医学主要以糖皮质激素、免疫抑制剂、扩瞳等治疗为主,但仍有易反复发作,长时间使用疗效降低等问题。中医药以辨证论治为特点,通过中医药与西药联合应用,在缩短疾病病程、减少疾病复发等方面具有一定优势。因此,此文选择近4年中西医治疗葡萄膜炎的临床研究进行学习认识和总结其优劣势。

电脑中频治疗仪联合电子针疗仪在腰椎间盘突出致坐骨神经痛中的应用效果研究

目的 探讨电脑中频治疗仪联合电子针疗仪在腰椎间盘突出致坐骨神经痛中的应用效果及对血清炎症因子的影响。方法 90例腰椎间盘突出致坐骨神经痛患者,按随机数字表法分为对照组和观察组,每组45例。对照组单纯给予电子针疗仪治疗,观察组给予电脑中频治疗仪联合电子针疗仪治疗。比较两组患者治疗前及治疗8周结束时视觉模拟评分法(VAS)、现时疼痛强度(PPI)、Oswestry功能障碍指数量表(ODI)、改良罗兰-莫里斯残疾问卷(RMDQ)、世界卫生组织生存质量测定量表简表(WHOQOL-BREF)评分及炎症因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平,临床疗效,不良反应发生情况。结果 治疗8周结束时,两组患者VAS、PPI、ODI、RMDQ评分低于本组治疗前,WHOQOL-BREF评分高于本组治疗前,且观察组患者VAS、PPI、ODI、RMDQ评分分别为(2.20±0.90)、(2.02±0.80)、(10.98±2.52)、(2.28±0.45)分,低于对照组的(4.25±1.18)、(2.65±0.96)、(17.45±2.32)、(5.84±0.66)分,WHOQOL-BREF评分(72.25±2.33)分高于对照组的(66.26±2.65)分,差异具有统计学意义(P<0.05)。治疗8周结束时,两组患者hs-CRP、IL-6、TNF-α水平均低于本组治疗前,且观察组患者hs-CRP、IL-6、TNF-α水平分别为(9.02±2.25)mg/L、(51.08±6.25)pg/ml、(22.75±3.46)pg/ml,低于对照组的(10.45±2.40)mg/L、(94.75±8.46)pg/ml、(55.18±6.60)pg/ml,差异具有统计学意义(P<0.05)。观察组患者临床总有效率为95.56%(43/45),明显高于对照组的80.00%(36/45),差异具有统计学意义(P<0.05)。两组患者治疗过程中未见明显不良反应。结论 电脑中频治疗仪联合电子针疗仪干预能有效改善腰椎间盘突出致坐骨神经痛患者的疼痛症状,促进腰椎功能恢复,改善躯体活动受限及生活质量,减轻局部炎症反应,值得临床推广应用。